Clinical Report: Inhibition of TYK2 in Skin Autoimmune Disorders

Overview

Revise to specify remission in both discoid lupus erythematosus and plaque psoriasis.

Background

Cutaneous lupus erythematosus (CLE) is an autoimmune disorder that can significantly impact patients' quality of life. Current treatment options are limited, often relying on therapies approved for systemic lupus erythematosus. The role of TYK2 in the pathogenesis of CLE presents a potential therapeutic target, making the exploration of TYK2 inhibitors like deucravacitinib clinically relevant.

Data Highlights

No numerical data available in the source material.

Key Findings

• Deucravacitinib led to complete remission of discoid lupus erythematosus in a patient refractory to standard treatments.
• The patient also presented with plaque psoriasis, which was effectively treated with ixekizumab prior to switching to deucravacitinib.
• Reflectance confocal microscopy provided non-invasive monitoring, confirming the resolution of inflammatory changes.
• TYK2 inhibition targets type I interferon pathways, central to the pathogenesis of cutaneous lupus.
• Current treatment guidelines do not yet incorporate TYK2 inhibitors for CLE, reflecting their investigational status.

Clinical Implications

Expand on the implications for clinical practice and potential patient outcomes.

Conclusion

Deucravacitinib shows promise as a novel therapeutic option for patients with treatment-refractory cutaneous lupus erythematosus and psoriasis. Further studies are warranted to establish its efficacy and safety in broader patient populations.

References

1. Journal of Crohn's and Colitis, 2023 -- Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis
2. Clinical Rheumatology, 2025 -- The Role of CAR-T Cell Therapy in Systemic Sclerosis Management
3. Concurrent Oral Pemphigus Vulgaris and Herpes Simplex Virus Infection in a Young Patient with Crohn’s Disease, 2024 -- A Unique Case of Oral Lesions During Anti-TNF Alpha and Immunomodulatory Treatment
4. New Lupus SLE Clinical Practice Guideline Released | ACR Convergence 2025 | American College of Rheumatology
5. Sotyktu for Psoriasis
6. Bone Marrow Transplantation — Highlights from the 46th Annual Conference of the European Society for Blood and Marrow Transplantation: Award Recipients (O001-O009)
7. Focus on Interferon Signature in Cutaneous Lupus Erythematosus: Novel Therapies From Better Understanding of the Pathogenesis
8. New Lupus SLE Clinical Practice Guideline Released | ACR Convergence 2025 | American College of Rheumatology
9. Sotyktu for Psoriasis